MR
MRNA.US Moderna Inc
- Market cap
- USD 87.1B
- P/E
- -
- P/B
- 13.22x
- ROE
- -38.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MRNA.US undervalued?
Graham numberThe Graham number of Moderna Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Moderna Inc fundamental analysis
No fundamental analysis for Moderna Inc yet.
Moderna Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Moderna Inc
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines;…
Full company profileModerna Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Moderna Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 108M | 206M | 123M | 48.0M | 274M | 17.7B | 18.9B | 6.85B | 3.20B | 1.94B | 2.46B |
| Gross Profit | 93.3M | 185M | -332M | 48.0M | 267M | 15.1B | 13.5B | 2.16B | 1.74B | 1.08B | 641M |
| Operating Income | -224M | -269M | -413M | -546M | -763M | 13.3B | 9.42B | -4.24B | -3.95B | -3.07B | -2.76B |
| EBITDA | -209M | -235M | -388M | -515M | -732M | 13.5B | 9.95B | -3.28B | -3.39B | -2.55B | -2.30B |
| Net Income | -216M | -256M | -385M | -514M | -747M | 12.2B | 8.36B | -4.71B | -3.56B | -2.82B | -2.62B |
| EPS | -0.58 | -0.68 | -4.74 | -1.55 | -1.96 | 28 | 20 | -12 | -9.27 | -7.25 | -6.09 |
| Balance Sheet | |||||||||||
| Total Assets | 1.42B | 1.08B | 1.96B | 1.59B | 7.34B | 24.7B | 25.9B | 18.4B | 14.1B | 12.3B | 13.5B |
| Total Liabilities | 575M | 459M | 432M | 415M | 4.78B | 10.5B | 6.74B | 4.57B | 3.24B | 3.69B | 6.63B |
| Shareholders' Equity | 842M | 625M | 1.53B | 1.17B | 2.56B | 14.1B | 19.1B | 13.9B | 10.9B | 8.65B | 6.84B |
| Cash & Short-term Investments | 1.06B | 756M | 1.69B | 1.10B | 4.61B | 10.7B | 9.90B | 8.60B | 7.03B | 5.80B | 5.17B |
| Total Debt | 37.6M | 88.4M | 113M | 132M | 237M | 916M | 1.20B | 1.24B | 747M | 1.31B | 4.18B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 66.7M | -331M | -331M | -459M | 2.03B | 13.6B | 4.98B | -3.12B | -3.00B | -1.87B | -3.62B |
| Capital Expenditure | 33.1M | 58.4M | 106M | 31.6M | 67.4M | 284M | 400M | 707M | 1.05B | 192M | 195M |
| Free Cash Flow | 33.6M | -390M | -437M | -491M | 1.96B | 13.3B | 4.58B | -3.83B | -4.06B | -2.07B | -3.81B |
| Ratios | |||||||||||
| ROE | -25.7% | -40.9% | -25.1% | -43.8% | -29.2% | 86.3% | 43.7% | -34.0% | -32.7% | -32.6% | -38.3% |
| ROA | -15.3% | -23.6% | -19.6% | -32.3% | -10.2% | 49.5% | 32.3% | -25.6% | -25.2% | -22.9% | -19.4% |
| Net Profit Margin | -199.5% | -124.3% | -314.0% | -1,070.1% | -272.2% | 68.8% | 44.3% | -68.8% | -111.3% | -145.2% | -106.3% |
| Debt to Equity | 0.04x | 0.14x | 0.07x | 0.11x | 0.09x | 0.06x | 0.06x | 0.09x | 0.07x | 0.15x | 0.61x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Moderna Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 270M | 0.71 | - |
| 2022 | USD 184M | 0.44 | 2.2% |
| 2021 | USD 124M | 0.29 | 1.0% |
| 2020 | USD 7.04M | 0.02 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | USD 1.48M | 0.00 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Moderna Inc
- Insiders 7.53%
- Institutions 77.52%
- Public & others 14.95%
- Shares outstanding 405M
- Free float 377M
Top funds holding MRNA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| American Funds Growth Fd of Amer A | 15.0M | 3.70% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 11.4M | 2.82% | +0.49% | Sep 2026 |
| Vanguard 500 Index Investor | 9.76M | 2.41% | +3.95% | Sep 2026 |
| Invesco QQQ Trust | 8.30M | 2.05% | -0.10% | Oct 2026 |
| Fidelity Growth Company Fund | 8.24M | 2.04% | +21.29% | Aug 2026 |
| Scottish Mortgage Ord | 5.56M | 1.37% | -24.87% | Sep 2026 |
| Fidelity OTC | 5.19M | 1.28% | -2.32% | Aug 2026 |
| iShares Core S&P 500 ETF | 4.95M | 1.22% | +0.17% | Oct 2026 |
| Fidelity 500 Index | 4.83M | 1.19% | +5.26% | Sep 2026 |
| American Funds IS® Growth 1 | 4.78M | 1.18% | +3.45% | Sep 2026 |
| Fidelity Contrafund | 4.68M | 1.16% | +7.99% | Sep 2026 |
| State Street® SPDR® S&P 500® ETF | 4.53M | 1.12% | -0.25% | Oct 2026 |
| Vanguard Small Cap Index | 4.04M | 1.00% | -50.79% | Sep 2026 |
| Vanguard MStar Mid Cap Index Instl | 3.85M | 0.95% | 0.00% | Sep 2026 |
| Vanguard International Growth Inv | 3.16M | 0.78% | -29.30% | Sep 2026 |
| iShares Biotechnology ETF | 2.84M | 0.70% | -0.32% | Oct 2026 |
| State Street®HlthCrSelSectSPDR®ETF | 2.72M | 0.67% | +0.88% | Oct 2026 |
| Vanguard MStar Small Cap Value Index | 2.63M | 0.65% | -49.57% | Sep 2026 |
| Capital Group Growth ETF | 2.56M | 0.63% | 0.00% | Oct 2026 |
| Fidelity Growth Company K6 | 2.37M | 0.59% | +20.05% | Aug 2026 |
Top institutions holding MRNA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 51.9M | 12.82% | +13.55% | Jun 2026 |
| BlackRock Inc | 30.6M | 7.56% | +3.25% | Jun 2026 |
| Vanguard Capital Management, LLC | 23.2M | 5.74% | +1.47% | Jun 2026 |
| Capital World Investors | 22.3M | 5.51% | +19.14% | Jun 2026 |
| State Street Corp | 15.7M | 3.89% | +5.82% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 15.6M | 3.85% | -0.22% | Jun 2026 |
| Baillie Gifford & Co Limited. | 11.4M | 2.83% | -37.18% | Sep 2026 |
| Geode Capital Management, LLC | 9.71M | 2.40% | +2.92% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 9.54M | 2.36% | +12.59% | Jun 2026 |
| Theleme Partners LLP | 8.06M | 1.99% | +0.12% | Jun 2026 |
| Two Sigma Investments LLC | 7.19M | 1.78% | -20.83% | Jun 2026 |
| Amvescap Plc. | 5.78M | 1.43% | +20.81% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 5.59M | 1.38% | +656.80% | Jun 2026 |
| Charles Schwab Investment Management Inc | 4.84M | 1.20% | +2.21% | Jun 2026 |
| The Goldman Sachs Group Inc | 4.67M | 1.15% | -29.25% | Jun 2026 |
| Flagship Ventures Management, Inc. | 4.63M | 1.14% | 0.00% | Jun 2026 |
| UBS Group AG | 4.46M | 1.10% | +1.25% | Jun 2026 |
| BNP Paribas Arbitrage, SA | 4.38M | 1.08% | +1.39% | Jun 2026 |
| NORGES BANK | 3.03M | 0.75% | +11.96% | Jun 2026 |
| Northern Trust Corp | 2.99M | 0.74% | +1.13% | Jun 2026 |
Moderna Inc company profile
- Company name
- Moderna Inc
- Ticker
- MRNA.US
- Exchange
- USA Stocks
- Listed since
- Dec 7, 2018
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4,700
- Fiscal year end
- December
- Address
- 325 Binney Street, Cambridge, MA, United States, 02142
- Phone
- 617 714 6500
- Website
- modernatx.com
About Moderna Inc
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Moderna Inc management
10- Mr. Stéphane Bancel M.B.A.CEO & Director · born 1973
- Dr. Stephen Hoge M.D.President · born 1976
- Mr. James M. MockChief Financial Officer · born 1977
- Ms. Shannon Thyme Klinger J.D.Chief Legal Officer & Corporate Secretary · born 1971
- Mr. Juan AndresChief Operating Officer · born 1965
- Ms. Lavina Talukdar CFASenior VP & Head of Investor Relations · born 1974
- Chris RidleyVP & Global Head of Communications
- Ms. Tracey FranklinChief People & Digital Technology Officer · born 1980
- Dr. Charbel Haber M.P.H., Ph.D.Senior VP & Head of Global Regulatory Science
- Mr. Patrick Norman BergstedtSenior Vice President of Commercial Vaccines · born 1962